Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

BACKGROUND: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes. The objective of this study was to investigate the impact of CYP2D6 polymorphisms on...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:BMC Cancer
Κύριοι συγγραφείς: Hennig, Ewa E., Piatkowska, Magdalena, Karczmarski, Jakub, Goryca, Krzysztof, Brewczynska, Elzbieta, Jazwiec, Radoslaw, Kluska, Anna, Omiotek, Robert, Paziewska, Agnieszka, Dadlez, Michal, Ostrowski, Jerzy
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BioMed Central 2015
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522133/
https://ncbi.nlm.nih.gov/pubmed/26232141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1575-4
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια